Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/30169
Title: Phase II trial to evaluate immunogenicity and safety of a new adjuvanted HBAI20 Hepatitis B vaccine in non-responders: BE RESPONDER
Authors: KOC, Ozgur 
De Smedt, Philippe
ROBAEYS, Geert 
Van Damme, Pierre
Almeida, Jorge
Falkenberg, Frank
Savekoul, Paul H.M.
Lashof, Astrid
Issue Date: 2019
Publisher: ELSEVIER SCIENCE BV
Source: JOURNAL OF HEPATOLOGY, 70, p. E149-E149
Notes: [Koc, Ozgur; Savelkoul, Paul H. M.; Lashof, Astrid Oude] Maastricht UMC, Maastricht, Netherlands. [Koc, Ozgur; Robaeys, Geert] Ziekenhuis Oost Limburg, Genk, Belgium. [Koc, Ozgur; Robaeys, Geert] Hasselt Univ, Hasselt, Belgium. [de Smedt, Philippe; Van Damme, Pierre] Antwerp Univ, Antwerp, Belgium. [Robaeys, Geert] Katholieke Univ Leuven, Leuven, Belgium. [Almeida, Jorge; Falkenberg, Frank] CyTuVax BV, Maastricht, Netherlands. [Falkenberg, Frank] CIRES GmbH, Bochum, Germany. [Savelkoul, Paul H. M.] Univ Amsterdam, Med Ctr, VUmc, Amsterdam, Netherlands.
Keywords: Gastroenterology & Hepatology
Document URI: http://hdl.handle.net/1942/30169
ISSN: 0168-8278
e-ISSN: 1600-0641
DOI: 10.1016/S0618-8278(19)30262-2
ISI #: 000463481700263
Category: M
Type: Journal Contribution
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
koc 1.pdf
  Restricted Access
Published version57.54 kBAdobe PDFView/Open    Request a copy
Show full item record

Page view(s)

64
checked on Jun 22, 2022

Download(s)

2
checked on Jun 22, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.